Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxycodone controlled release - Purdue Pharma

Drug Profile

Oxycodone controlled release - Purdue Pharma

Alternative Names: OxiContin; Oxycodone controlled release - Purdue; Oxycodone extended release - Purdue; Oxycodone hydrochloride controlled-release; OxyContin; OxyContin Neo; OxyContinTR; OxyNeo

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Purdue Pharma
  • Developer Mundipharma International; Napp Pharmaceutical Group; Purdue Pharma; Shionogi
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cancer pain; Pain; Postoperative pain

Most Recent Events

  • 28 Aug 2018 Assertio Therapeutics signs settlement agreement with Purdue Pharma as a follow-up to its patent infringement lawsuit (related to oxycodone controlled release) filed in U.S. District Court for the District of New Jersey
  • 07 Sep 2017 Mundipharma completes a phase I trial in Pain in China (NCT03403504)
  • 08 Jul 2015 Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office confirms the patentability of all challenged claims in the inter partes review proceedings initiated by Purdue Pharma against two Depomed patents
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top